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P apillomaviruses infect stratifying epithelial cells and cause benign tumors or papillomas. In certain circum-stances, viral infection can lead to malignant transfor-mation, and one goal of this review is to discuss the mechanisms by which human papillomaviruses (HPVs) 
cause cancer. All papillomaviruses are composed of two comple-
mentary strands of DNA with about 8000 nucleotides on each of 
the two strands. Their genome is present as a covalently closed circle 
(plasmid or episome) within the nucleus of infected cells. Papillo-
maviruses are defined by both the animal species they infect and 
their nucleic acid sequence. Whereas all papillomaviruses are 
highly related, the differences in their DNA sequences are used to 
distinguish viral genotypes by DNA-DNA hybridization. Using 
criteria to define how great the differences must be in a new isolate, 
nearly 70 HPV genotypes have been reported [1] . These DNA 
sequence differences result in amino acid changes among the viral 
encoded proteins. Divergence is also found in the viral regulatory 
region, including the cis-acting sites for assembly of viral and cell 
encoded factors that control viral gene expression and replication. 
These variations in coding and non coding sequences must be re-
sponsible for the species specificity and pathogenicity of each viral 
genotype, and have been used to construct a phylogenetic tree of 
HPV evolution [2,3] . 
Whereas there are multiple HPV genotypes, these can be catego-
rized into three classes. The first set includes those predominantly 
found in cutaneous lesions, most commonly types 1,2,3, and 4. The 
second category of HPV is a large group isolated in epidermo-
dysplasia verruciformis (EV) . In this disease, patients have lifelong 
warts, often from an early age. EV represents one of the earliest 
recognized examples of a human virus infection leading to malig-
nancy. In EV, individuals infected with specific HPV types, most 
notably types 5 and 8, develop squamous cell carcinomas from their 
warts. However, whereas there are many lesions on an individual 
infected with HPV 5 or 8, only a minority proceed to malignancy. 
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Because these cancers are usually located on sun-exposed skin, ultra-
violet (UV) light is believed to be a co-factor in tumor induction. 
The third class of HPV s primarily infects mucosal epithelia such 
as the oropharynx and anogenital region. As observed with EV, only 
a subset of these have a predilection for progressing to squamous cell 
carcinoma. HPV 6 and 11 are commonly found in genital warts and 
cervical papillomas, whereas HPV 16 and 18 a.re less frequent. The 
frequency is opposite in cervical, penile, vulvar and anal cancers. 
Most cervical carcinomas contain types 16, 18,31,35, etc., whereas 
HPV 6 and 11 are rare (estimated to be 1- 5%) [4-6]. The former 
set ofHPVs is called "high risk," whereas HPV 6 and 11 are termed 
"low risk." High-risk HPV types can infect cutaneous skin and have 
been identified in squamous cell carcinomas. Because specific sub-
sets of HPVs are found in cutaneous squamous carcinomas in EV 
and in cervical cancer, this observation implies that the HPVs are 
causative agents for these tumors. Both the latent period (estimated 
to be 5 -20 years) between infection and development of cancer, and 
the fact that all warts do not become malignant, even with "high-
risk" HPV's, indicate that infection with HPV is necessary but not 
sufficient for development of cancer. Under the influence of the 
virus life cycle, changes must occur within the cell during the pro-
gression from papilloma to neoplasia. These may be consequences 
of viral infection (see below) or co-factors, such as ultraviolet light 
or smoking. 
BIOLOGY OF PAPILLOMAVIRUS INFECTION 
All papillomavirus genomes encode 9 - 10 open reading frames and 
with variable splicing have the potential to synthesize 12-15 gene 
products. The reading frames labeled "E," for early, represent those 
genes in bovine papilloma virus (BPV), which were thought to be 
involved in episomal replication in cultured cells. The late, or "L," 
genes encode the viral capsid proteins. The number after E or L 
refers to the size of the reading frame peptide, with 1 being the 
largest. These designations are not rigorous, because E4 is not essen-
tial for viral DNA replication and probably serves a late function 
(see below). In this review, I briefly describe the events of the life 
cycle and how the papillomavirus gene products mediate these 
events. Particular emphasis is placed on the viral oncogenes E5, E6, 
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and E7 and the cellular proteins with which they interact. However, 
whereas these viral genes are oncogenic in cultured cells, their pri-
mary function must be to assure viral replication and not direct 
conversion of the host cell to a malignant state. Malignant progres-
sion should be viewed as the pathogenic consequences induced by 
these oncoproteins as they establish the viral replication life cycle. 
Entry Papillomaviruses gain access to the host by direct implan-
tation through physical breaks in the epithelial barrier. The specific 
receptor and the specific cell type that bind the virus upon entry 
h ave not been identified. It is assumed that virus initially infects the 
basal cell , although this has not been proved, and it is conceivable 
that pathogenic viral infection can initiate in the upper layers of the 
epithelium. Basal cells are assumed to be infected with one or two 
copies of the circular viral DNA per cell; however, a few such 
molecules are not detectable with current technology. The ex-
trachromosomal viral DNA resident in basal cells is believed to 
replicate in concert with normal cell division. Presumably, the viral 
genome is transported, along with the daughter cells, to upper levels 
of the epithelium. It is in these highly differentiated strata that viral 
RNAs are expressed at substantial levels [7]. It is presumed that 
differentiation-specific events transduce a stimulatory signal for 
viral transcription and DNA replication. Thus papillomaviruses 
replicate to high numbers only in expendable, terminally differen-
tiated cells that are destined to be sloughed off, and they are not lytic 
like other viruses. There is no evidence that papillomaviruses dis-
seminate within the infected animal through viremia or another 
systemic route. 
Exit After many copies of the circular vira l DNA are synthesized 
in the upper strata, these genomes are incorporated into a particle, or 
cap sid, which consists of the L1 and L2 proteins. The vira l capsid 
protects its DNA during traversal through the epithelium as the 
keratinocytes terminally differentiate, as well as after being shed 
into the environment. Importantly, papillomaviruses do not bud 
from the cell's plasma membrane and thus do not incorporate a 
membrane-derived lipid envelope, which would cause them to be 
sensitive to environmental stresses such as heat, soaps, or desicca-
tion. Presumably the capsid binds receptors on the host cell. Having 
assembled these new viruses, papilloma viruses are carried along 
with stratifying cells to the stratum corneum, from where they are 
released as the epithelium undergoes its normal maturation pro-
gram. Several groups have reported that high-level expression of 
HPV and BPV L1 and L2 genes results in their self assembly into 
normal-appearing capsids, which have been demonstrated to expose 
native epitopes [8 -12]. These virus- like particles may be of utility 
for serologic diagnosis of HPV infection and as vaccines. 
Inunune Response All viruses probably evolve mechanisms to 
avoid host surveillance. For example, mutations in critical viral 
antigens develop at high frequency in influenza and human immu-
nodeficiency virus (HIV) . Viruses such as herpes simplex and vari-
cella-zoster induce a strong immune response but avoid immune 
surveillance through latency, i.e., these viruses can remain as DNA 
buried in the cell's chromosomes, only to reactivate, produce their 
proteins, and release viral particles at a later time. Other viruses such 
as measles or HIV directly kill lymphocytes, whereas others release 
proteins that inhibit host defenses. How papilloma viruses avoid 
host immune surveillance is not known. Papillomavirus-encoded 
proteins are present at exceedingly low levels in the lower levels of 
the epithelium and may therefore reduce exposure to the appropri-
ate immune effector cells. In addition, the enveloped viruses (see 
Entry) synthesize proteins that are inserted into the cell's plasma 
membrane prior to budding and release, and it is these proteins that 
are strongly antigenic and recognized by the host immune response. 
Papillomaviruses do not assemble in this manner, and indeed viral 
particles form in the nucleus. Thus papillomaviruses have evolved a 
means of replication that probably reduces exposure to the immune 
system. 
Coordination of the Viral Replication Cycle After entering 
the appropriate host cell, the virus must establish the proper order in 
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which its own genes will be expressed. The full circuitry that con-
trols papilloma virus gene expression is not known. Within the 
non-coding region of each virus are DNA sequences that are recog-
nized by cellular transcription factors [13 -17]. The papillomavirus 
genotypes vary in the type, array, and position of these sites, which 
probably have important consequences for pathogenicity. 
In addition to these binding sites for cellular factors, papillomavi-
ruses encode a DNA binding protein in a gene called E2. E2 binds 
the inverted palindrome 5' ACCG NNNN CGGT 3' with very 
high affinity (~1O- 11 M) [18] , and multiple copies of this DNA 
palindrome are found in every papilloma virus genome [19]. Their 
placement often varies among different genotype groups. E2 can 
stimulate, and in certain instances repress, viral transcription [20-
22] and is also required for viral DNA replication (see below). 
~hen E2 binds its recognition site, it usually stimulates transcrip-
tion from the nearby promoters in a classical "enhancer" mode. 
The E2 proteins average about 400 amino acids with a mono-
meric molecular weight of approximately 50 kilodaltons (KD) and 
have distinct functional domains [23 - 25]. The carboxy terminal 
100 amino acids of all papillomavirus E2 proteins constitutes the 
DNA binding domain. T his small region is sufficient for sequence-
specific D NA binding and dimerization, which E2 must do to bind 
DNA [26]. The atomic structure of the BPV E2 protein bound to its 
cognate D N A site has been solved and found to fo ld as an unusual 
B-barrel dimer with a DNA recognition helix crossing each mono-
mer [27]. 
The amino terminal half of the E2 protein is necessary for stimu-
lation of gene expression, so these amino acids must interface with 
the cell's transcription machinery. This region of E2 represents its 
transcription activation domain. When E2 binds a specific segment 
on the viral D NA through its DNA binding domain, its transcrip-
tion activation domain recnlits the cell ular factors that lead to syn-
thesis of the viralmRNA. One such factor may be Spl, although 
there is evidence that E2 activates transcription in concert with a 
variety of basal promoter factors [28,29]. 
The E2 DN A binding and transcription activation dom.ains share 
considerable homology among the papillomaviruses. Between 
these two regions is a variable stretch of residues that al'e not con-
served, and are genera lly thought to represent a " flexibl e hinge." 
The E4 reading frame overlaps this E2 hinge region and the papillo-
maviruses differ substantially in their E4 proteins. E4 is not essential 
for viral transcription, replication, or transformation in vitro and is 
believed to serve a role in maturation of the viral capsid alld escape of 
the viral particle fr0111 the dense intermediate filament network of 
the epithelial cell [30,31]. 
The precise determinants that regulate expression of the viral 
genome have yet to be resolved, but most likely involve a complex 
interplay between the cellular factors that recognize the viral ge-
nome and the E2 protein. As presented previously, papillomaviruses 
do not express high levels of their RNAs and proteins until the late 
stages of epithelial differentiation. To restrict overexpression of the 
viral genes, BPV and HPV has evolved tnlncated E2 proteins to act 
as transcriptional repressors [32-35]. These repressors lack the 
amino terminal trallscription activation domain but retain a func-
tional DNA binding domain [36] . Therefore they compete with 
full-length E2 proteins for occupancy of the E2 binding sites on the 
viral genome. In addition, the E2 protein normally is a dimer, and 
formation of a heterodimer between a full- length and truncated E2 
protein represents another mechanism for the inactivation of the 
E2-induced transcription [37]. Both full-l ength and truncated E2 
can repress vira l transcription by interfering with the binding of 
cellular transcription factors to their recognition sites in the regula-
tory region. As such, E2 has dual roles in viral transcription: activa-
tion and repression. Dominance of the latter function may reduce 
vira l expression (and replication) in basal and parabasal keratino-
cytes. 
Replication of the Viral Genome The viral DNA must be 
selectively replicated to produce a large number of infectious prog-
eny in each cel l. This would normall y be very detrimental except 
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that PV replication occurs in terminally differentiated cells. This 
highlights the central paradox of papillomavirus replication: it 
begins in a non-replicating cell layer in which the multitude of 
enzymes necessary for DNA synthesis are thought not to be present. 
Because papillomaviruses do not encode a DNA polymerase or the 
associated factors necessary to duplicate DNA, they must induce the 
cell to provide the enzymes and substrates necessary for DNA repli-
cation. Consequently, the virus must mobilize these cellular factors 
to reproduce the viral genome. It is hypothesized that the viral 
oncogenes described below trick the cell into providing the neces-
sary materials and enzymes to synthesize DNA. It is the E2 and E1 
proteins that recruit t~ese to the viral DNA. .. . 
Papillomavirus utihzes two protems, E2 and El, to Identify theLr 
genomes among the mass of host DNA. Mutations in the viral El 
gene interfere with autonomous replication of the viral DNA (re-
viewed in [38]). An important observation was that the E1 protein 
binds to E2 protein [39-41]. It is believed thatE2 and El each bring 
a set of cellular factors to the DNA, and these factors replicate the 
viral DNA. El weakly binds a specific DNA sequence in the viral 
regulatory region [42], and this activity of El is greatly enhanced 
when it is complexed with E2 [43]. In BPV, the E1 binding site is 
adjacent to E2 sites, and this segment of viral DNA is sufficient for 
autonomous replication in murine cells when E 1 and E2 proteins are 
expressed [44]. The E1 protein has helicase activity, which is neces-
sary for separating the DNA strands prior to their replication [45]. 
Both BPV and HPV E1 and E2 are necessary for viral DNA replica-
tion [46-48]. 
IN VITRO MODELS TO STUDY 
PAPILLOMA VIRUS BIOLOGY 
To understand the events triggered by papillomavirus infection and 
their biologic implications, ill vitro models using cultured cells have 
been employed. Transformation assays measure the ability of a gene 
to alter a variety of growth parameters. In some assays, the rate of 
cell division is increased, the nutritional requirements of the cells 
are altered, and they become growth factor independent, or the cells 
become resistant to agents that induce terminal differentiation (such 
as calcium). Another model incorporates the use of cells that are 
contact inhibited and remain as a monolayer at confluence. Intro-
duction of an oncogene results in the loss of contact inhibition, and 
the transformed cells pile up on top of another as they continue to 
proliferate. These piled-up cells, or foci, are tumorigenic in immu-
no compromised (nude) mice, whereas the original cell line does not 
form tumors in animals. This experimental system is commonly 
used to test whether a single gene or set of genes can induce malig-
nant transformation hI vitro. In another system, primary normal cells 
such as keratinocytes are used because they divide only for a limited 
number of generations, and ultimately senesce. Continuous prolif-
eration in vitro of normal human cells is exceedingly rare. Introduc-
ing specific papillomavirus genes causes cultured keratinocytes to 
become "immortal." These cells appear morphologically un-
changed but have acquired the ability to grow continuously, yet are 
not tumorigenic. 
It is possible to reproduce more closely the normal keratinocyte 
differentiation program in vitro by cultivating keratinocytes at the 
air-media interface. In this model normal human keratinocytes or 
cervical cells undergo orderly stratification and differentiation 
when grown on a raft of permeable collagen and fibroblast matrix 
floating on the nutritional media. Introduction of either the whole 
viral genome or its oncogenes into these keratinocytes results in 
disruption of their maturation program, and these PV -containing 
keratinocytes histologically resemble early squamous cell carci-
noma [49-51]. The low-risk HPVs do not induce these changes 
when introduced into the raft model. 
Until recently it has not been possible to cultivate human papillo-
mavirus in vitro, even using the raft model. It has been assumed that 
whereas this system approaches formation of a normal-appearing 
epithelium, some unknown critical step was not reproduced. This 
has greatly impeded understanding viral pathogenesis because it is 
not possible to test the effects of elimination of a specific viral gene's 
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function in the viral replicative cycle or pathogenesis. The difficulty 
in producing papillomavirus in vitro probably reflects the fact that its 
reproduction is strictly coordinated with epithelial differentiation 
and that papillomavirus transcription is tightly regulated. 
Using the raft culture system, two groups have recently reported 
production of viral particles in vitro. In both, keratinocytes from an 
HPV-infected clinical specimen were expanded in culture and 
placed onto the collagen matrix. One group, using cells from a 
cervical lesion that contained autonomously replicating HPV 31, 
found that treatment of cells with multiple cycles of tumor-pro-
moting agent (TP A) induced expression of the viral proteins and 
assembly of viral particles [52J. These HPV 31 viruses appear to be 
infectious. In the second system, infected cervical tissue was placed 
on a raft, and it was discovered that when this matrix included 
murine fibroblasts, they would provide the correct milieu for proper 
differentiation of the epithelium and for the viral reproductive cycle 
[53]. These successes provide much excitement, as it may be possible 
to derive from this model a full understanding of the connections 
between virus replication and epithelial cell differentiation. Their 
major limitation at present is the inability to introduce a cloned viral 
DNA genome into a normal, uninfected cell and achieve replication 
of the viral genome and production of infectious viral particles. For 
example, to test the relevance of a specific DNA sequence that 
might control expression of the viral capsid genes one might begin 
by mutating the candidate locus and testing whether virus can be 
produced. It can be expected that these impediments will be re-
solved and that these advances will be of major utility for the study 
of human papillomaviruses. 
Animal-based models have also been successful for producing 
specific HPVs. In this system normal human epithelial cells from 
cervix or skin are infected with HPV and placed under the renal 
capsule of an immunodeficient (nude) mouse for extended period, 
usually several months [54,55]. In this protected environment the 
epithelial cells differentiate and form a papilloma in which papillo-
mavirus particles can be found. This has been successful for isolates 
ofHPV 11; however, successful production of high-risk HPV parti-
cles has not been reported. Another model utilized a cell line derived 
from an HPV 16-infected cervical lesion in which the viral DNA 
was maintained extrachromosomal. Incubation of these cells in a 
chamber on the back of a nude mouse has been reported to allow 
stratified differentiation and production of HPV 16 particles [56]. 
DO PAPILLOMAVIRUSES CAUSE CANCER? 
The association of specific HPV types with the development of 
epithelial malignancies, such as in epidermodysplasia verruciformis 
and cervical cancer, strongly support the association of HPV and 
cancer. The primary goal of the viral reproductive cycle cannot be 
oncogenesis, as suggested by the observation that viral particles are 
not detected in cervical dysplasias and cancers. Because papilloma-
virus replication is strictly limited to differentiated cells of the epi-
thelium the early causation of a dedifferentiated state would not 
provide an appropriate foundation for viral replication. 
MOLECULAR BIOLOGY OF 
PAPILLOMA VIRUS ONCOGENES 
The transforming properties of papillomavirus were first studied 
using BPV. Large quantities of BPV could be harvested from cattle 
papillomas. Infection of murine cell lines (NIH 3T3 and C127) 
with BPV caused the cells to become transformed by multiple cri-
teria: loss of contact inhibition, anchorage-independent growth, 
and tumorigenicity in mice. Because BPV DNA replicated autono-
mously in these cells, the replication functions of viral proteins 
could also be studied. Ll and L2 were not expressed and hence viral 
particles do not assemble. However, whereas similarities exist be-
tween the oncogenes of BPV and HPV, there are also differences, 
and the following discussion will concentrate on the three onco-
genes of HPV: E6, E7, and E5. For a comprehensive survey of their 
molecular biology the reader is referred to [57,58]. 
As HPV 16 and 18 were associated with the development of 
anogenital malignancies, the initial investigations of HPV trans-
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fOrIning potential began with the genes from these viruses. Intro-
duction of both their E6 and E7 genes into primary human kerati-
nocytes rendered these cells resistant to calcium- and serum-induced 
terminal differentiation [59,60]. E6 and E7 cooperate in immortali-
zation of primary rodent embryo fibroblasts and primary human 
keratinocytes [61-70]. When the high-risk E6 and E7 genes were 
transferred into epithelial cells cultured in the raft model, the cells 
exhibited features of dysplastic alterations with disorganized differ-
entiation and abnormal mitoses. These high-risk E6 and E7 genes 
also immortalize other cell types that papillomaviruses never infect, 
such as smooth muscle cells [71]. Interestingly, HPV 16 E6 alone 
induced immortalization of normal human mammary epithelial 
cells, providing a useful model for the study of early breast cancer 
and indicating that this viral gene has targeted a conserved and 
common cell growth pathway [72]. These are remarkable findulgs, 
because the generation of immortal cell lines from any normal 
human tissue is an extremely rare event, even with other tumor 
viruses, oncogenes, and chemical inducers. These immortal cells are 
not tumorigenic in animals; thus not all steps in neoplastic progres-
sion are provided by these genes. Continued passage of the HPV 18 
containing immortal keratinocytes resulted in outgrowth of fully 
malignant cells [73]. This was probably due to further genetic 
changes in the cells, which may be a result of the papillomavirus 
oncogenes mechanisms of action (see below). 
Important insights into the mechanism of action of the high-risk 
HPV E6 and E7 genes were gained from comparison with other 
DNA tumor viruses. The transforming proteins of adenovirus, sim-
ian virus (SV) 40, and polyomavirus were known to bind an over-
lapping set of cellular proteins. The identification of these common 
targets as tumor suppressor gene products led to the discovery, by 
analogy, that the high-risk HPV transforming proteins E6 and E7 
complex ill vitro with the p53 and retinoblastoma (Rb) proteins, 
respectively. 
The precise mechanisms by which p53 and Rb are involved in cell 
proliferation are not fully understood (reviewe~ in [~4]). Their sig-
nificance cannot be overstated, because mutatIOns In p53 are the 
most common genetic abnormalities identified in human cancers 
[75]. This obse.rvation suggested th~t p53 ~light regula~e .c~1l divi-
sion, and that Its loss would result In continuous cell diVISIOn and 
malignancy. However, p53 'knockout' mice, in which both p53 
alleles have been deleted, grew normally illl/tero but as adults devel-
oped tumors at high frequency. Because the mice were viable, the 
absence of p53 does not automatically result in unchecked cellular 
proliferation (reviewed in [76]) . p53 is now believed to act as a 
'guardian' that protects cellular DNA [76]. When the cell's DNA is 
damaged (for example, by UV or x-ray irradiation), p53 arrests cell 
division and may allow time for DNA damage to be repaired. In-
deed, p53 levels are elevated m UV-irradiated skin, and p53 muta-
tions consistent with UV damage are found in cutaneous squamous 
cell carcinomas [77 ,78]. 
p53 has been reported to stimulate expression of two important 
genes. The first, mdm2, was identified as a protein that complexes 
with p53 and inhibits its transcriptional activation function. Be-
cause p53 induces expression of mdm2, it appears that the latter may 
be a component of a regulatory feedback loop. The second gene, 
WAF-I, was identified as a target for p53 activation and gives a very 
important clue to p53 function [79]. This 21-kDa protein was 
simultaneously and independently isolated as an inhibitor of cyclin-
dependent kinase [80] . These findings link the function of p53 to 
control of cell division and provide insights into how p53 deregula-
tion may lead to cancer. 
Rb was first identified as a gene that was found mutated in 
kindreds with hereditary risk of cancers, including retinoblastoma 
of the eye in early childhood. The Rb protein is a very large, 105-
kDa nuclear phosphoprotein, and is a member of a family of pro-
teins that appear to directly regulate entry into cell cycle division. 
THE E6 ONCOPROTEIN 
Papillomavirus E6 proteins consist of about 150 amino acids be-
lieved to coordinate a zinc atom through two sets of cysteine repeats 
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(cysteine x-x cysteine zinc fingers, where x is any amino acid) 
[81,82]. The human papilloma viruses E6 proteins have moderate 
homology at the amino acid level, indicating that while they share 
functions, they may also differ. HPV 16 E6 has a half-life of 30 - 60 
min and is present in transformed and cancer-derived cell lines at 
extremely low levels [83]. Several reports have demonstrated that 
high- and low-risk E6 genes can stimulate transcription equally, 
suggesting that this function may be relevant to viral reproduction 
rather than correlate with oncogenic potential [68 ,84,85]. 
The high-risk HPV 16 and 18 E6 proteins interact with p53, as do 
SV40 large T and adenovirus Elb [86] . HPV and other viruses 
presumably interfere with the ability of p53 to block cell division 
and DNA synthesis so that viral DNA can replicate to high levels. 
Whereas errors in the viral DNA may occur durmg its synthesis and 
may not be repaired, viruses probably compensate by producing 
large numbers of infectious particles and evolving efficient mecha-
nisms of spreading to the next host. Indeed these mutations permit 
genetic drift that can circumvent immune defenses. SV40 and ade-
novirus prevent p53-mediated cell cycle arrest by synthesizing large 
amounts oflarge T and Elb, which effectively hold p53 in inactive 
complexes. E6 protem eliminates p53 functions through a novel 
mechanism. It has been shown that formation of the E6-p53 com-
plex ill J/itro induced p53 degradation through a ubiquitin-depen-
dent mechanism [87] . High-risk E6 binds a 100-kDa protein, called 
E6-AP (for E6 Associated Protein), which appears be required for 
complex formation between E6 and p53 and is necessary for degra-
dation of p53 [88] . The gene for E6-AP has recently been cloned and 
is a member of the ubiquitin pathway for protein degradation [89] . 
It has been reported that low-risk (HPV 6 and 11) E6 also binds p53 
but with reduced efficiency, yet are not capable of inducing p53 
degradation [85]. This is controversial, for another group found that 
low-risk E6 did not bind p53 i'l J/itro [86]. Usulg another assay they 
reported that low-risk E6 proteins have the ability to stunulate 
degradation of a target protein with which it is in complex [90]. It is 
likely that the different interpretations reflect inability to accurately 
measure quantitative differences using ill vitro assays rather than 
invoking an alternative mechanism of action for low-risk E6 that 
does not involve p53. The induction of p53 degradation ill vitro also 
appears to hold in vivo. Introduction of HPV 16 E6 into both pri-
mary human keratinocytes and mammary epithelial cells .leads to a 
marked decrease in the half-life of p53 [62,68,91]. 
Despite these important findin gs, there are several lines of evi-
dence that suggest that E6 possesses other functions. DPV E6 does 
not bind p53, yet fully transforms murine Cl27 cells [92]. BPV E6 
and HPV 6 E6, which do not induce p53 degradation ill J/itro or ill 
vivo, can immortalize human mammary epithelial cells, although 
they are much less efficient than HPV 16 [93]. HPV 8, which is 
found in cutaneous squamous cell carcinoma in epidermodysplasia 
verruciformis, does not bind or degrade p53 ill vitro [94], but, similar 
to BPV E6, transforms mouse cells [95]. These putative non-p53 
functions are yet to be determined. 
THE E7 ONCOPROTEIN 
The E7 oncoprotein is an acidic 98 amino acid phosphoprotein that 
has been localized to the nuclear matrix [96] . Two cysteine-x-x-cys-
terne motifs in the carboxy terminus mediate zinc binding and di-
merization [97]. Recognition of the amino acid similarities between 
the HPV E7 proteins and the DNA tUIll.or virus transforming pro-
teins SV40 Large T and adenovirus Ela facilitated elucidation of the 
biochemical properties ofE 7 [98,99]. These similarity regions were 
shown to bind the tumor suppressor gene product Rb and the related 
p107 proteins [100-103] . Both Rb and pl07 regulate cell cycle 
division but act at different stages. Detailed analyses have found that 
the pl07 binding region of E7 overlaps with but can be distin-
guished from the Rb binding domain [104,105]. 
It is thought that when E7 binds Rb or pl07, a transcription factor 
normally bound to Rb/p107 is released, because E7 binds the same 
pocket as the factor [106,107]. This factor, called E2F, is a se-
quence-specific DNA binding protein, and the DNA motif it rec-
ognizes is found in many genes essential for cell division {reviewed 
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in [108]). Recently, E2F and a related family of genes have been 
cloned [109,110]. There is evidence that the events induced by the 
Rb/pl07 association with E7 can eventuate in a complex yet coor-
dinated cascade of positive and negative signals that allow a cell to 
replicate its DNA and divide. Other regions ofE7 bind additional 
growth-related cellular factors. HPV 16 E7 has bee~l identified in 
complexes with histone kinase [111], p33cdk2 and cycl1l1A [112], and 
casein kinase II [113 ,1 14], which phosphorylates high-risk E7 more 
efficiently than it does low risk. Because Rb preferentially binds to 
phosphorylated E7 protein, this phosphorylation may in part relate 
to the oncogenic potential of high-risk E7 [llS]. 
Both HPV 16 and 18 E7 induced focus formation in murine cell 
line transformation assays [116,1 17]. Consistent with its interaction 
with Rb/pl07, introduction ofE7 alone into primary human kera-
tinocytes resulted in an increased rate of proliferation for an ex-
tended period of time, although they eventually senesced [118]. 
Introduction of high-risk E7 can induce keratinocyte immortaliza-
tion in the absence of E6, although this was a rare occurrence and 
presumably other changes occurred in the cells that bypass the pS3 
pathway. U sing very high-efficiency retroviral-mediated infection 
of primary human keratinocytes, it has been shown that low-risk 
HPV 6 E7 can cooperate with high-risk E6 to induce immortaliza-
tion of primary human keratinocytes, and in the alternative mixing 
experiment, HPV 6 E6 cooperated with HPV 16 E7 to induce 
immortalization, although in both instances, the efficiency was less 
than with high-risk E6 and E7 [119]. These data suggest that the 
difference between the high- and low-risk E7 genes may be the 
efficiency at which they perform similar functions. Low-risk E7 
also complexes with Rb/pl07, and whereas there are quantitative 
differences in Rb/pl07 association affinities with high-risk E7 
[120 -122], the specific interactions that are responsible for high-
risk E7 inducing transformation of cultured cells have not been 
definitively proved [123,124] . As with E6, there remain unidenti-
fied properties of E7 that are required for its transforming activities. 
For example , mutations in E7 that do not affect Rb/p107 associa-
tion interfere with its ability to transform and immortalize the cells 
[124]. 
The cottontail rabbit papillomavirus (CRPV) model has recently 
been developed and permits evaluation of the biologic requirements 
for specific CRPV genes irl vivo. Remarkably, inoculation of CRPV 
DNA into rabbit skin resulted in papillomas in which CRPV DNA 
replicated autonomously and virus particles were synthesized 
[12S,126] . Surprisingly, rabbit skin injected with viral genomes 
carrying mutations in the CRPV E7 gene that abrogated Rb binding 
ability also formed papillomas, indicating that the interaction with 
Rb was not absolutely necessary for development of a wart or for 
replication of the virus [126,127]. These data suggest that Rb bind-
ing by E7 may be a function important for malignant transforma-
tion; however, it is possible that pl07 binding is more relevant to 
papilloma formation and viral reproduction. 
THE ES ONCOPROTEIN 
The ES protein represents another fascinating and ingenious means 
that papillomaviruses have evolved to prime the cell for viral repro-
duction . An ES gene has been identified in bovine, deer, elk, and 
some human papillomaviruses. These animal viruses produce a con-
comitant dermal fibroblast proliferation (fibropapillomas), along 
with an epithelial component, in their hosts. ES proteins have not 
been established in all the HPVs, in part because it is so small; the 
BPV ES gene product is only 44 amino acids and was initially 
overlooked as too tiny to do anything. The HPV ES gene is often 
deleted or its gene not expressed in human cervical carcinomas, 
whereas E6 and E7 are always synthesized. This suggests that ES 
plays a role at an early stage of viral carcinogenesis. BPV -1 and HPV 
6c ES have been reported to transform established murine fibroblast 
cell lines, whereas HPV 16 ES did not [92,128,129]. Introduction of 
HPV 16 ES into established murine keratinocyte lines induced their 
tumorigenicity in nude mice, suggesting a potential role in human 
malignancy [130]. 
Much of the current understanding of the biochemistry ofES has 
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been derived from studies using BPV. The BPV ES protein has been 
isolated from transformed rodent cells as a 14-kDa disulfide-linked 
dimer [131]. A pair of cysteine residues separated by one amino acid 
is believed to mediate dimerization. Immunoelectron microscopy 
detection of the BPV ES protein has revealed that the majority is 
oriented within the luminal leaflet of the Golgi stacks, with signifi-
cantly less in the plasma membrane [132] . The abundance of ES 
within the Golgi suggests the possibility that ES may interact with a 
growth factor receptor (see below) in transit to the plasma mem-
brane. Recently, BPV -1 ES protein has been identified in both basal 
and upper layer keratinocytes in naturally occurring bovine fibro-
papillomas [133]. 
The small size ofES facilitated detailed structure-function analy-
ses. The amino terminal two-thirds of the protein is extremely 
hydrophobic and has been shown to be responsible for membrane 
localization. Within this hydrophobic transmembrane domain is a 
single polar amino acid, glutamine (amino acid 17 in BPV ES), and 
its presence (or that of another charged residue) is important for the 
transforming abi lity of BPV ES [134]. The carboxy terminal 16 
amino acids are charged and are absolutely required for transforma-
tion of murine cells [13S]. This segment has been reported to be 
oriented extracellularly, but is probably too small to form a growth 
factor receptor. 
As with E6 and E7, progress in elucidating the mechanism 
through which ES acts has resulted from studies that identify cellu-
lar factors that bind ES. A small 16-kDa protein (called p16) has 
been found to associate with BPV ES [136] . p16 has been identified 
as a component of the vacuolar H + ATPases [137 -139]. This pro-
ton transporter is responsible for acidification of cellular compart-
ments such as Iysosomes. The region of ES that binds p16 has been 
mapped to the transmembrane hydrophobic region and complex 
formation is believed to involve glutamine 17. These observations 
have led to a model in which the hydrophobic region mediates 
insertion ofES into hydrophobic cellular membranes and the region 
of glutamine 17 attracts and binds to the p16 component of the 
cellular proton pump. Presumably this interaction inhibits acidifi-
cation of Iysosomes and may thus interfere with receptor down-
regulation (see below). 
Recognizing that ES was too small to possess enzymatic function 
yet was localized to the same cellular compartments as growth fac-
tor receptors, it was discovered that introduction ofBPV ES caused 
increased levels of the epidermal growth factor (EGF) receptor in 
mouse cells, and as a consequence, the murine fibroblasts became 
exquisitely sensitive to transformation by EGF [140] . In the ES-
transformed cells, these EGF receptors were maintained at the 
plasma membrane in the active phosphorylated form, suggesting 
that they were not being downmodulated, as they normally are 
subsequent to ligand binding. This is consistent with the hypothesis 
that ES interferes with receptor processing as a consequence of 
inhibiting p16-mediated acidification of Iysosomes. Consistent 
with this, stimulation of transformation by BPV ES was not specific 
for the EGF receptor, and similar synergistic effects were observed 
with other receptors. A specific target of BPV -1 ES may be the 
platelet-derived growth factor (PDGF) receptor, and a physical 
complex between ES and the PDGF receptor has been reported 
[141,142] . 
The EGF and PDGF receptors are activated by distinct ligands 
and in turn transduce signa ls through separate pathways. How can 
BPV ES interact with different growth factor receptors? These ob-
servations may be explained by ES possessing two different activities 
that can distinguish the receptors. It has been found that the cys-
teines in the carboxy terminus of ES are necessary for transforma-
tion through the PDGF receptor, and that the ES transmembrane 
domain and glutamine 17 arc also critical [143]. The hydrophobic 
portion of each ES monomer in the disulfide-bonded dimer binds a 
p16 molecule, which in turn complexes with a PDGF-receptor 
monomer. Thus, bridged by p16, ES may mediate PDGF receptor 
dimerization and activation. An alternate mechanism would be nec-
essary for the EGF class of receptors, because they do not require 
dimerization for activation. It has been reported that the carboxy 
terminus ofBPV E5 physically binds a 125-kDa protein in the alpha 
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adaptin family [144]. This association required the cysteines to be 
reduced, that is, not disulfide linked, which is opposite of the PDGF 
receptor model. It is speculated that via the adaptin complex, E5 
may interfere directly with EGF receptor downregulation, as adap-
tins are responsible for the processing of this class of receptors. 
These observations predict dual functions of E5, which depend on 
the particular growth factor receptor expressed in a papilloma virus-
infected cell. 
The role ofE5 in viral pathogenesis has also been examined using 
the CRPV inoculation model. Injection of DNA containing inacti-
vating E5 mutations into the skin of domestic rabbits resulted in 
reduced efficiency of papilloma formation [145] . This indicates a 
role ofE5 in the viral reproductive cycle, although it does not appear 
to be essential. Perhaps the function of E5 is to establish the appro-
priate aC.tiv.ated cellular. environment in .a cell that is. terminally 
differentlatmg, thus settll1g the stage for Viral DNA repitcatlon that 
is more directly induced by E7, with inhibitory checkpoints re-
moved by E6 and perhaps E7. 
FURTHER EVIDENCE THAT HPV CAUSES CANCER 
There are several lines of evidence that support the role of HPV in 
causing cancer. As presented above, the E5, E6, and E7 genes inter-
act with cellular proteins that control cell growth. High-risk E6 and 
E7 induce the immortalization of normal human keratinocytes (and 
other cell types) and morphologically transform rodent cells. Inser-
tion ofHPV 16 E6 and E7 into the mouse genome (transgenic) leads 
to epithelial tumors in tissues that express the viral genes [146,147]' 
and similar results have been reported using CRPV [148]. Analyses 
of in vivo malignancies also support the role of the virus in oncogen-
esis . HPV DNA is found in greater than 90% of cervical cancers, 
and the metastases also retain the HPV DNA. Interestingly, the 
viral genome is often integrated in cancer cells, although it is not 
known whether this precedes neoplastic conversion or is a conse-
quence of the multiple genetic changes that occur in tumor cells. 
Nonetheless, the HPV E6 and E7 genes are always retained and 
expressed in the tum.or t~ssue, wl~ereas the ?ther viral genes are often 
disrupted or lost dunng lI1tegratlon. Cell hnes denved from cerVical 
carcinomas produce HPV E6 and E7 proteins, for instance HeLa 
cells, synthesizing HPV 18 E6 and E7 after decades in culture. 
Treatment of cervical carcinoma cells with antisense oligonucleo-
tides or introduction of antisense DNA into these cells inhibited E6 
and E7 expression and resulted in decreased cell proliferation and 
loss of tumorigenicity [149-152]. Cell hybrids of normal fibro-
blasts crossed with HeLa cells led to decreased expression ofE6 and 
E7 and loss of He La tumorigenicity [153]. These observations imply 
that the continued expression of E6 and E7 in both fresh cervical 
cancers and cervical tumor cell lines is necessary for the malignant 
state. 
The epidemiologic association between HPV and cancer now 
seems certain. Several large studies have indicated that infection 
with specific HPV types is associated with a relative risk estimated 
to range from 10 to 200 times for development of cervical neoplasia 
[154]. Several recent studies have 'provided important information 
and have been reviewed recently [155,156]. First, repeated testing 
detects HPV in cytologically normal cervical specimens. These may 
represent subclinical infection or presence of the virus in secretions 
without true infection. There is reason to believe that HPV infec-
tion of the cervix may be transient, such that in the infected cell the 
virus does not replicate or the infected cells are desquamated and 
lost. Prospective studies have suggested that infection of the cervix 
with high-risk HPV progresses to cervical intraepithelialneoplasia 
(CIN) stage 2 or 3 over a relatively brief period of perhaps 2-3 
years. The success of Pap smear screening in lowering the incidence 
of cervical cancer indicates that most invasive cervical cancers do not 
arise from latent, subclinical HPV infection but develop from ab-
normal intraepithelial precursor lesions. 
HOW DOES HPV CAUSE CANCER? 
The critical obstacle that papillomaviruses must overcome is that 
viral DNA must be synthesized in cells that are not replicating. The 
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papillomavirus oncogenes are thought to induce the cellular events 
necessary to synthesize DNA. E1 and E2 usurp these pathways for 
replication of the viral genom.e. The E6 and E7 oncogenes inactivate 
the p53 and Rb pathways and thus abrogate cellular control mecha-
nisms that regulate DNA synthesis. This is relevant because p53 
might recognize that DNA is being synthesized outside the cell 
cycle and shut down the metabolic pathways involved in DNA 
replication. HPV 16 E6 was shown to block growth arrest that 
occurs normally after UV radiation and allowed the cells to con-
tinue to divide [157] . 
Under ordinary conditions there are no detrimental effects of 
papillomavirus induction of DNA replication enzymes in the upper, 
terminally differentiated squamous cells. Malignancy may arise 
from the stimulation of cell division by the viral oncogenes in an 
inappropriate cell before it has been irreversibly converted to the 
non-replicating population. Perhaps in this case there is unregulated 
duplication of the host DNA, resulting in gross chromosomal ab-
normalities. Alternatively, it is possible that neoplasia develops due 
to unregulated expression of the viral oncogenes. For example, it 
may be that loss of autonomous replication leads to integration and 
uncoupling of a normal mechanism that keeps E6 and E7 expressed 
at low levels. As a result of E6 inhibition of the normal p53 growth 
arrest function prior to DNA repair, il~ured cells may accumulate 
DNA damage and pathogenic mutations. Cells containing E7 have 
also been shown to develop an increased rate of mutations [158]. 
Cultured keratinocytes immortalized by HPV 16 or 18 also display 
chromosomal instability. The genetic alterations that occur in the 
dividing cells may often be detrimental to survival, but the accumu-
lation of such events over years most likely permits the selection and 
establishment of cancerous cells that proliferate and invade in an 
unregulated manner. 
One significance of the elucidation of the functions and events 
triggered by the viral oncoproteins E5 , E6, and E7, and the viral 
transcription/replication proteins E1 and E2, is that these provide 
insights into normal metabolic pathways operative in epithelial 
cells. Furthermore, these discoveries should permit the rationale 
design of anti-viral and anti-cancer agents that we may someday use 
to treat our patients with HPV infection. 
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